hydrogen carbonate has been researched along with Renal Insufficiency, Chronic in 119 studies
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.
hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic kidney disease with metabolic acidosis is common in older people, but the effectiveness of oral sodium bicarbonate therapy in this group is unclear." | 9.34 | Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. ( , 2020) |
| "We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD." | 9.20 | The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. ( Altuntaş, A; Bayram, D; İnal, S; Kıdır, V; Orhan, H; Tuğrul Sezer, M, 2015) |
| "Thus, dietary alkali treatment of metabolic acidosis in CKD that is less severe than that for which KDOQI recommends therapy reduces kidney angiotensin II activity and preserves eGFR." | 6.79 | Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. ( Goraya, N; Jo, CH; Simoni, J; Wesson, DE, 2014) |
| "Chronic kidney disease with metabolic acidosis is common in older people, but the effectiveness of oral sodium bicarbonate therapy in this group is unclear." | 5.34 | Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. ( , 2020) |
| "We assume that decreasing uric acid levels with allopurinol treatment seems to be helpful in restoring endothelial functions, preventing metabolic acidosis and slowing down the progression of CKD." | 5.20 | The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. ( Altuntaş, A; Bayram, D; İnal, S; Kıdır, V; Orhan, H; Tuğrul Sezer, M, 2015) |
| " The aim of this study was to evaluate the effect of a 3-month oral sodium bicarbonate administration on arterial wall stiffness, arterial pressure and serum nutritional markers in non-dialysed patients with chronic kidney disease (CKD) stages 3−5 and metabolic acidosis." | 4.12 | Effects of Oral Bicarbonate Supplementation on the Cardiovascular Risk Factors and Serum Nutritional Markers in Non-Dialysed Chronic Kidney Disease Patients. ( Kurnatowska, I; Nowicka, M; Nowicki, M; Szczecińska, K; Wajdlich, M, 2022) |
| "The aim of this study was to assess the effect of three oral potassium supplements (potassium gluconate tablets [PGT], potassium gluconate granules [PGG] and potassium citrate granules [PCG]) on hypokalemia and serum bicarbonate in cats with chronic kidney disease (CKD)." | 3.96 | Retrospective study of the efficacy of oral potassium supplementation in cats with kidney disease. ( Quimby, JM; Sieberg, LG, 2020) |
| "The primary outcome is kidney disease progression defined as the development of end-stage kidney disease, a sustained decline in eGFR of >40% from baseline or death due to kidney failure." | 3.30 | Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis. ( Bushinsky, DA; Inker, L; Klaerner, G; Li, E; Mathur, VS; Parsell, D; Perkovic, V; Stasiv, Y; Tangri, N; Walker, M; Wesson, DE; Wheeler, DC, 2023) |
| "Veverimer was effective in treating metabolic acidosis in women with CKD, and significantly improved how they felt and functioned." | 3.11 | Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial. ( Bushinsky, DA; Li, E; Mathur, VS; Tangri, N; Wesson, DE, 2022) |
| "Metabolic acidosis is a complication of chronic kidney disease (CKD) that increases risk of CKD progression, and causes bone demineralization and muscle protein catabolism." | 3.11 | Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial. ( Li, E; Mathur, VS; Wesson, DE, 2022) |
| "Metabolic acidosis is frequent in chronic kidney disease (CKD) and is associated with accelerated progression of CKD, hypercatabolism, bone disease, hyperkalemia, and mortality." | 3.01 | Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences. ( Aguirre, M; Avello, A; Carrasco-Muñoz, CG; Carriazo, S; Fernandez-Fernandez, B; Fernandez-Prado, R; Gonzalez-de-Rivera, M; Martin-Cleary, C; Ortiz, A; Perez-Gomez, MV; Sanchez-Niño, MD; Villalvazo, P, 2023) |
| " CKD stage 3-4 patients with serum HCO3- <22 mEq/L were randomized to either receive oral sodium bicarbonate with high target bicarbonate level of 25 ± 1 or standard level of 22 ± 1 mEq/L as control group using protocol-based titration of dosage adjustment." | 2.94 | Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients. ( Chulakadabba, A; Eiam-Ong, S; Kittiskulnam, P; Praditpornsilpa, K; Srijaruneruang, S; Thokanit, NS; Tungsanga, K, 2020) |
| "Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bone demineralisation and is associated with adverse kidney outcomes and mortality." | 2.90 | Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. ( Bushinsky, DA; Klaerner, G; Li, E; Mathur, V; Parsell, D; Stasiv, Y; Tangri, N; Wesson, DE, 2019) |
| "Metabolic acidosis is an important complication of CKD, and where it "falls" in the priority schema of CKD care will depend upon the generation of strong clinical evidence." | 2.82 | Importance of Metabolic Acidosis as a Health Risk in Chronic Kidney Disease. ( Scialla, JJ; Vincent-Johnson, A, 2022) |
| "In this cohort of patients with type 2 diabetes with nephropathy, serum bicarbonate level associations with kidney disease end points were not retained after adjustment for estimated glomerular filtration rate, which is in contrast to results of earlier studies in nondiabetic populations." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Thus, dietary alkali treatment of metabolic acidosis in CKD that is less severe than that for which KDOQI recommends therapy reduces kidney angiotensin II activity and preserves eGFR." | 2.79 | Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate. ( Goraya, N; Jo, CH; Simoni, J; Wesson, DE, 2014) |
| "Oral sodium bicarbonate has been shown to improve nutritional status and preserve renal function in CKD." | 2.75 | Oral sodium bicarbonate improves thyroid function in predialysis chronic kidney disease. ( Disthabanchong, S; Treeruttanawanich, A, 2010) |
| "Metabolic acidosis is defined as a pathologic process that, when unopposed, increases the concentration of hydrogen ions (H+) in the body and reduces the bicarbonate (HCO3-) concentration." | 2.61 | Hyperchloremic normal gap metabolic acidosis. ( Clegg, DJ; Palmer, BF, 2019) |
| "Although hyperkalemia is a well-recognized complication of CKD, the prevalence rates of hyperkalemia (14%-20%) and hypokalemia (12%-18%) are similar." | 2.55 | Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes. ( Gilligan, S; Raphael, KL, 2017) |
| "Metabolic acidosis is a common complication of chronic kidney disease; it is typically caused by the accumulation of sulfate, phosphorus, and organic anions." | 2.53 | The choice of dialysate bicarbonate: do different concentrations make a difference? ( Basile, C; Lomonte, C; Rossi, L, 2016) |
| "Metabolic acidosis was one of the earliest complications to be recognized and explained pathologically in patients with CKD." | 2.52 | Current status of bicarbonate in CKD. ( Dobre, M; Hostetter, TH; Rahman, M, 2015) |
| "Metabolic acidosis is common in patients with chronic kidney disease (CKD), particularly once the glomerular filtration rate (GFR) falls below 25 ml/min/1." | 2.47 | Consequences and therapy of the metabolic acidosis of chronic kidney disease. ( Kraut, JA; Madias, NE, 2011) |
| "Sodium bicarbonate treatment was prescribed for 17." | 1.91 | Metabolic acidosis is undertreated and underdiagnosed: a retrospective cohort study. ( Bohm, C; Collister, D; Ferguson, TW; Funk, SE; Komenda, P; Reaven, NL; Rigatto, C; Tangri, N; Whitlock, RH, 2023) |
| "Renal osteodystrophy is a state of impaired bone quality and strength." | 1.91 | Comprehensive Associations between Acidosis and the Skeleton in Patients with Kidney Disease. ( Agarwal, S; Aponte, MA; Brown, DD; Dempster, D; Fusaro, M; Guo, XE; Kamanda-Kosseh, M; Kumar, J; Levy, RV; McMahon, DJ; Melamed, ML; Misof, BM; Nickolas, TL; Reidy, K; Zhou, H, 2023) |
| "Although metabolic acidosis is known as a potential complication of chronic kidney disease (CKD), there is limited information concerning the association between metabolic acidosis and clinical outcomes." | 1.72 | Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis. ( Fukasawa, H; Furuya, R; Kaneko, M; Uchiyama, Y; Yasuda, H, 2022) |
| "Metabolic acidosis is associated with chronic kidney disease (CKD) progression and mortality, but the association of race/ethnicity with incident metabolic acidosis and/or its adverse outcomes in patients with CKD is unknown." | 1.72 | Relationship between Metabolic Acidosis and Chronic Kidney Disease Progression across Racial and Ethnic Groups: An Observational, Retrospective Cohort Study. ( Funk, SE; Mathur, V; Reaven, N; Tangri, N; Wesson, DE, 2022) |
| "Metabolic acidosis is a treatable condition with substantial adverse effects on human health." | 1.72 | Associations of Metabolic Syndrome and Abdominal Obesity with Anion Gap Metabolic Acidosis among US Adults. ( Abramowitz, MK; Kane, J; Lambert, DC; Slaton, A, 2022) |
| "Both high and low pre-ESRD CO2 levels (≥28 and <18 mEq/L) during 6 months prior to dialysis transition and rate of CO2 decline >4 mEq/L/year during 1 year before dialysis initiation were associated with greater post-ESRD all-cause, CV, and non-CV mortality." | 1.62 | Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD. ( Catabay, CJ; Hsiung, JT; Kalantar-Zadeh, K; Kleine, CE; Kovesdy, CP; Kraut, J; Lee, Y; Murray, V; Obi, Y; Park, C; Rhee, CM; Soohoo, M; Streja, E; Tantisattamo, E; Wenziger, C, 2021) |
| "Metabolic acidosis was defined as a serum bicarbonate level of <22 mmol/L, and baPWV was used as a surrogate of arterial stiffness." | 1.51 | Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: Results from the KNOW-CKD Study. ( Ahn, C; Han, M; Kang, E; Kim, HJ; Kim, YS; Lee, KB; Oh, KH; Ryu, H; Sung, S, 2019) |
| "Metabolic acidosis is commonly found in patients with chronic kidney disease (CKD), and its causes are: impaired ammonia excretion, reduced tubular bicarbonate reabsorption and insufficient renal bicarbonate production in relation to the amount of acids synthesised by the body and ingested with food." | 1.48 | Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology. ( Adamczak, M; Madziarska, K; Masajtis-Zagajewska, A; Mazanowska, O; Stompór, T; Więcek, A, 2018) |
| "Insulin sensitivity was measured by hyperinsulinemic euglycemic clamp." | 1.43 | Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease. ( Curtin, L; de Boer, IH; Himmelfarb, J; Ikizler, HO; Kestenbaum, B; Ruzinski, J; Utzschneider, KM; Zelnick, L, 2016) |
| "Increased arrhythmia risk in kidney disease is one of the main predominant factors in increased mortality and sudden cardiac death." | 1.43 | Effect of metabolic acidosis on QT intervals in patients with chronic kidney disease. ( Aydin, MZ; Aypak, C; Dede, F; Turgut, D; Yenigun, EC, 2016) |
| "Proteinuria was obtained from a 24-h urine collection." | 1.40 | In chronic kidney disease, serum α-Klotho is related to serum bicarbonate and proteinuria. ( Cuerq, C; Drai, J; Dubourg, L; Fouque, D; Hadj-Aissa, A; Hage, V; Laville, M; Lemoine, S; Pelletier, S, 2014) |
| "Seventy-four bone fractures and 47 hospitalizations due to fracture were observed during the follow-up period." | 1.40 | Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD stage 5D patients (MBD-5D). ( Akizawa, T; Fukagawa, M; Fukuhara, S; Kato, A; Kido, R; Kurita, N; Onishi, Y, 2014) |
| "Metabolic acidosis is an inevitable complication associated with progressive loss of kidney function." | 1.40 | [Acid-base status in patients treated with peritoneal dialysis]. ( Bašić-Jukić, N; Blaslov, K; Katalinić, L; Kes, P; Pasini, E, 2014) |
| "Hyperkalemia was defined as a serum potassium concentration greater than 5." | 1.39 | Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency. ( Flynn, J; Okamura, D; Thompson, K; Zhou, L, 2013) |
| "Urea kinetic model was used to assess solute clearance." | 1.39 | Dialysis adequacy in Chinese anuric peritoneal dialysis patients. ( Ma, S; Shao, Y; Tian, X; Wang, T; Xu, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.84) | 29.6817 |
| 2010's | 75 (63.03) | 24.3611 |
| 2020's | 43 (36.13) | 2.80 |
| Authors | Studies |
|---|---|
| Imenez Silva, PH | 1 |
| Unwin, R | 1 |
| Hoorn, EJ | 1 |
| Ortiz, A | 2 |
| Trepiccione, F | 1 |
| Nielsen, R | 1 |
| Pesic, V | 1 |
| Hafez, G | 1 |
| Fouque, D | 2 |
| Massy, ZA | 1 |
| De Zeeuw, CI | 1 |
| Capasso, G | 1 |
| Wagner, CA | 2 |
| Shah, LN | 1 |
| Matheson, MB | 1 |
| Furth, SL | 3 |
| Schwartz, GJ | 2 |
| Warady, BA | 3 |
| Wong, CJ | 1 |
| Babovic, B | 1 |
| Djuranovic, S | 1 |
| Mihaljevic, O | 1 |
| Sakic, K | 1 |
| Borovinic Bojovic, J | 1 |
| Radoman Vujacic, I | 1 |
| Belada Babovic, N | 1 |
| Jovanovic, V | 1 |
| Boskovic, V | 1 |
| Radovanovic, S | 1 |
| Wong, MMY | 1 |
| Renouf, D | 1 |
| Zheng, Y | 1 |
| Sheriff, Z | 1 |
| Levin, A | 1 |
| Mathur, VS | 3 |
| Wesson, DE | 10 |
| Tangri, N | 7 |
| Li, E | 5 |
| Bushinsky, DA | 4 |
| Fukasawa, H | 1 |
| Kaneko, M | 1 |
| Uchiyama, Y | 1 |
| Yasuda, H | 1 |
| Furuya, R | 1 |
| Szczecińska, K | 1 |
| Wajdlich, M | 1 |
| Nowicka, M | 1 |
| Nowicki, M | 1 |
| Kurnatowska, I | 1 |
| Ash, SR | 2 |
| Batlle, D | 1 |
| Kendrick, J | 2 |
| Oluwatosin, Y | 1 |
| Pottorf, W | 1 |
| Brahmbhatt, Y | 1 |
| Guerrieri, E | 1 |
| Fried, L | 1 |
| Murray, AM | 1 |
| Slinin, Y | 1 |
| Tupper, DE | 1 |
| Pederson, SL | 1 |
| Davey, C | 1 |
| Gilbertson, DT | 1 |
| Drawz, P | 3 |
| Mello, R | 1 |
| Hart, A | 1 |
| Johansen, KL | 2 |
| Reule, S | 1 |
| Rossom, R | 1 |
| Knopman, DS | 1 |
| Ahmad, H | 1 |
| Wertin, T | 1 |
| Zhang, Y | 3 |
| Neher, JO | 1 |
| Auten, B | 1 |
| Ho, JQ | 1 |
| Verghese, J | 1 |
| Abramowitz, MK | 6 |
| Brown, DD | 3 |
| Carroll, M | 1 |
| Ng, DK | 2 |
| Levy, RV | 2 |
| Greenbaum, LA | 1 |
| Kaskel, FJ | 2 |
| Melamed, ML | 6 |
| Dauber, A | 1 |
| Meremo, A | 1 |
| Paget, G | 1 |
| Duarte, R | 1 |
| Dickens, C | 1 |
| Dix-Peek, T | 1 |
| Bintabara, D | 1 |
| Naicker, S | 1 |
| Catalano, A | 1 |
| Gaudio, A | 1 |
| Bellone, F | 1 |
| La Fauci, MM | 1 |
| Xourafa, A | 1 |
| Gembillo, G | 1 |
| Basile, G | 1 |
| Natale, G | 1 |
| Squadrito, G | 1 |
| Corica, F | 1 |
| Morabito, N | 1 |
| Santoro, D | 2 |
| Vincent-Johnson, A | 1 |
| Scialla, JJ | 4 |
| Nagami, GT | 2 |
| Kraut, JA | 5 |
| Hansen, NM | 1 |
| Berg, P | 1 |
| Rix, M | 1 |
| Pareek, M | 1 |
| Leipziger, J | 1 |
| Kamper, AL | 1 |
| Astrup, A | 1 |
| Vaarby Sorensen, M | 1 |
| Salomo, L | 1 |
| Whitlock, RH | 1 |
| Ferguson, TW | 2 |
| Komenda, P | 1 |
| Rigatto, C | 1 |
| Collister, D | 2 |
| Bohm, C | 1 |
| Reaven, NL | 2 |
| Funk, SE | 3 |
| Inker, L | 1 |
| Klaerner, G | 3 |
| Parsell, D | 3 |
| Perkovic, V | 1 |
| Stasiv, Y | 3 |
| Walker, M | 1 |
| Wheeler, DC | 1 |
| Mathur, V | 4 |
| Reaven, N | 1 |
| Lambert, DC | 2 |
| Kane, J | 2 |
| Slaton, A | 2 |
| Chandra, S | 1 |
| Ravula, S | 1 |
| Errabelli, P | 1 |
| Spencer, H | 1 |
| Singh, M | 1 |
| McMahon, DJ | 1 |
| Agarwal, S | 1 |
| Dempster, D | 1 |
| Zhou, H | 1 |
| Misof, BM | 1 |
| Guo, XE | 1 |
| Kamanda-Kosseh, M | 1 |
| Aponte, MA | 1 |
| Reidy, K | 1 |
| Kumar, J | 2 |
| Fusaro, M | 1 |
| Nickolas, TL | 1 |
| Fernandez-Prado, R | 1 |
| Villalvazo, P | 1 |
| Avello, A | 1 |
| Gonzalez-de-Rivera, M | 1 |
| Aguirre, M | 1 |
| Carrasco-Muñoz, CG | 1 |
| Fernandez-Fernandez, B | 1 |
| Martin-Cleary, C | 1 |
| Carriazo, S | 1 |
| Sanchez-Niño, MD | 1 |
| Perez-Gomez, MV | 1 |
| You, Z | 1 |
| Andrews, E | 1 |
| Farmer-Bailey, H | 1 |
| Moreau, K | 1 |
| Chonchol, M | 1 |
| Steele, C | 1 |
| Wang, W | 2 |
| Nowak, KL | 1 |
| Patel, N | 1 |
| Kim, HJ | 1 |
| Kang, E | 1 |
| Ryu, H | 1 |
| Han, M | 1 |
| Lee, KB | 1 |
| Kim, YS | 1 |
| Sung, S | 1 |
| Ahn, C | 1 |
| Oh, KH | 1 |
| Horwitz, EJ | 1 |
| Dobre, MA | 1 |
| Zhang, L | 2 |
| Lo, Y | 1 |
| Mitch, WE | 1 |
| Hostetter, TH | 2 |
| Kramer, H | 1 |
| Kittiskulnam, P | 1 |
| Srijaruneruang, S | 1 |
| Chulakadabba, A | 1 |
| Thokanit, NS | 1 |
| Praditpornsilpa, K | 1 |
| Tungsanga, K | 1 |
| Eiam-Ong, S | 1 |
| Al-Kindi, SG | 1 |
| Sarode, A | 1 |
| Zullo, M | 1 |
| Rajagopalan, S | 1 |
| Rahman, M | 6 |
| Hostetter, T | 4 |
| Dobre, M | 7 |
| Roem, J | 1 |
| Reidy, KJ | 1 |
| Mak, RH | 1 |
| Roger, SD | 1 |
| Spinowitz, BS | 1 |
| Lerma, EV | 1 |
| Fishbane, S | 1 |
| Martins, JG | 1 |
| Quinn, CM | 1 |
| Packham, DK | 1 |
| Madias, NE | 5 |
| Angeloco, LRN | 1 |
| Arces de Souza, GC | 2 |
| Romão, EA | 1 |
| Frassetto, L | 1 |
| Chiarello, PG | 1 |
| Kahyaoglu, M | 1 |
| Karaduman, A | 1 |
| Geçmen, Ç | 1 |
| Candan, Ö | 1 |
| Güner, A | 1 |
| Cakmak, EO | 1 |
| Bayam, E | 1 |
| Yılmaz, Y | 1 |
| Çelik, M | 1 |
| Izgi, IA | 1 |
| Kirma, C | 1 |
| Raphael, KL | 5 |
| Kohn, OF | 1 |
| Patschan, D | 1 |
| Patschan, S | 1 |
| Ritter, O | 1 |
| Tantisattamo, E | 1 |
| Murray, V | 1 |
| Obi, Y | 1 |
| Park, C | 1 |
| Catabay, CJ | 1 |
| Lee, Y | 1 |
| Wenziger, C | 1 |
| Hsiung, JT | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Rhee, CM | 1 |
| Kraut, J | 1 |
| Kovesdy, CP | 2 |
| Kalantar-Zadeh, K | 1 |
| Streja, E | 1 |
| Hultin, S | 1 |
| Johnson, DW | 1 |
| Badve, SV | 1 |
| Khairallah, P | 1 |
| Isakova, T | 1 |
| Asplin, J | 2 |
| Hamm, L | 1 |
| Sharma, K | 1 |
| Leonard, M | 1 |
| Miller, E | 1 |
| Jaar, B | 2 |
| Brecklin, C | 1 |
| Yang, W | 3 |
| Wang, X | 2 |
| Feldman, H | 2 |
| Wolf, M | 4 |
| Harambat, J | 1 |
| Kunzmann, K | 1 |
| Azukaitis, K | 1 |
| Bayazit, AK | 1 |
| Canpolat, N | 1 |
| Doyon, A | 1 |
| Duzova, A | 1 |
| Niemirska, A | 1 |
| Sözeri, B | 1 |
| Thurn-Valsassina, D | 1 |
| Anarat, A | 1 |
| Bessenay, L | 1 |
| Candan, C | 1 |
| Peco-Antic, A | 1 |
| Yilmaz, A | 1 |
| Tschumi, S | 1 |
| Testa, S | 1 |
| Jankauskiene, A | 1 |
| Erdogan, H | 1 |
| Rosales, A | 1 |
| Alpay, H | 1 |
| Lugani, F | 1 |
| Arbeiter, K | 1 |
| Mencarelli, F | 1 |
| Kiyak, A | 1 |
| Dönmez, O | 1 |
| Drozdz, D | 1 |
| Melk, A | 1 |
| Querfeld, U | 1 |
| Schaefer, F | 1 |
| Peng, Z | 1 |
| Wang, J | 1 |
| Yuan, Q | 1 |
| Xiao, X | 1 |
| Xu, H | 1 |
| Xie, Y | 1 |
| Huang, L | 1 |
| Zhong, Y | 1 |
| Ao, X | 1 |
| Zhao, M | 1 |
| Tao, L | 1 |
| Zhou, Q | 1 |
| Hamm, LL | 4 |
| Chen, W | 1 |
| Goraya, N | 2 |
| Gilligan, S | 1 |
| Brown, D | 1 |
| Rodrigues Neto Angéloco, L | 2 |
| Almeida Romão, E | 1 |
| Garcia Chiarello, P | 2 |
| Căpuşă, C | 1 |
| Ştefan, G | 1 |
| Stancu, S | 1 |
| Lipan, M | 1 |
| Tsur, LD | 1 |
| Mircescu, G | 1 |
| Chazot, C | 1 |
| Jean, G | 1 |
| Joly, D | 1 |
| Sozio, SM | 1 |
| McAdams-DeMarco, M | 1 |
| Biasibetti, E | 1 |
| Martello, E | 1 |
| Bigliati, M | 1 |
| Biasato, I | 1 |
| Cocca, T | 1 |
| Bruni, N | 1 |
| Capucchio, MT | 1 |
| Lorenz, G | 1 |
| Mayer, CC | 1 |
| Bachmann, Q | 1 |
| Stryeck, S | 1 |
| Braunisch, MC | 1 |
| Haller, B | 1 |
| Carbajo-Lozoya, J | 1 |
| Schmidt, A | 1 |
| Witthauer, S | 1 |
| Abuzahu, J | 1 |
| Kemmner, S | 1 |
| Angermann, S | 1 |
| Koneru, N | 1 |
| Wassertheurer, S | 1 |
| Bieber, R | 1 |
| Heemann, U | 1 |
| Madl, T | 1 |
| Pasch, A | 2 |
| Schmaderer, C | 1 |
| Adamczak, M | 2 |
| Masajtis-Zagajewska, A | 1 |
| Mazanowska, O | 1 |
| Madziarska, K | 1 |
| Stompór, T | 1 |
| Więcek, A | 2 |
| Yee, J | 1 |
| Maruta, Y | 1 |
| Hasegawa, T | 1 |
| Yamakoshi, E | 1 |
| Nishiwaki, H | 1 |
| Koiwa, F | 1 |
| Imai, E | 1 |
| Hishida, A | 1 |
| Skiba, K | 1 |
| Gojowy, D | 1 |
| Szotowska, M | 1 |
| Bartmańska, M | 1 |
| Kolonko, A | 1 |
| Cierpka, L | 1 |
| Quiñones, H | 1 |
| Hamdi, T | 1 |
| Sakhaee, K | 1 |
| Moe, OW | 1 |
| Pak, CYC | 1 |
| Banerjee, T | 1 |
| Crews, DC | 1 |
| McCulloch, CE | 1 |
| Saydah, S | 1 |
| Rios Burrows, N | 1 |
| Saran, R | 1 |
| Gillespie, B | 1 |
| Bragg-Gresham, J | 1 |
| Powe, NR | 1 |
| Sieberg, LG | 1 |
| Quimby, JM | 1 |
| Palmer, BF | 1 |
| Clegg, DJ | 1 |
| Chen, J | 4 |
| Horwitz, E | 1 |
| Lora, CM | 1 |
| Nessel, L | 1 |
| Ojo, A | 1 |
| Scialla, J | 1 |
| Steigerwalt, S | 1 |
| Teal, V | 1 |
| Watson, EL | 1 |
| Kosmadakis, GC | 1 |
| Smith, AC | 1 |
| Viana, JL | 1 |
| Brown, JR | 1 |
| Molyneux, K | 1 |
| Pawluczyk, IZ | 1 |
| Mulheran, M | 1 |
| Bishop, NC | 1 |
| Shirreffs, S | 1 |
| Maughan, RJ | 1 |
| Owen, PJ | 1 |
| John, SG | 1 |
| McIntyre, CW | 1 |
| Feehally, J | 1 |
| Bevington, A | 1 |
| Thompson, K | 1 |
| Flynn, J | 1 |
| Okamura, D | 1 |
| Zhou, L | 1 |
| Chang, TI | 1 |
| Oh, HJ | 1 |
| Kang, EW | 1 |
| Yoo, TH | 1 |
| Shin, SK | 1 |
| Kang, SW | 1 |
| Choi, KH | 1 |
| Han, DS | 1 |
| Han, SH | 1 |
| Kanda, E | 2 |
| Ai, M | 2 |
| Kuriyama, R | 2 |
| Yoshida, M | 2 |
| Shiigai, T | 2 |
| Lee, YJ | 1 |
| Cho, S | 1 |
| Kim, SR | 1 |
| Simoni, J | 1 |
| Jo, CH | 1 |
| Goldenstein, L | 2 |
| Driver, TH | 2 |
| Fried, LF | 2 |
| Rifkin, DE | 1 |
| Patel, KV | 1 |
| Yenchek, RH | 1 |
| Harris, TB | 1 |
| Kritchevsky, SB | 1 |
| Newman, AB | 1 |
| Sarnak, MJ | 2 |
| Shlipak, MG | 4 |
| Ix, JH | 4 |
| Katz, R | 1 |
| Hoofnagle, AN | 2 |
| Siscovick, DS | 1 |
| Kestenbaum, B | 3 |
| de Boer, IH | 3 |
| Ying, J | 1 |
| Greene, T | 2 |
| Bayram, D | 1 |
| Tuğrul Sezer, M | 1 |
| İnal, S | 1 |
| Altuntaş, A | 1 |
| Kıdır, V | 1 |
| Orhan, H | 1 |
| Hage, V | 1 |
| Pelletier, S | 1 |
| Dubourg, L | 1 |
| Drai, J | 1 |
| Cuerq, C | 1 |
| Lemoine, S | 1 |
| Hadj-Aissa, A | 1 |
| Laville, M | 1 |
| Kato, A | 1 |
| Kido, R | 1 |
| Onishi, Y | 1 |
| Kurita, N | 1 |
| Fukagawa, M | 1 |
| Akizawa, T | 1 |
| Fukuhara, S | 1 |
| Chase, HS | 1 |
| Hirsch, JS | 1 |
| Mohan, S | 1 |
| Rao, MK | 1 |
| Radhakrishnan, J | 1 |
| Bürki, R | 1 |
| Mohebbi, N | 1 |
| Bettoni, C | 1 |
| Serra, AL | 1 |
| Guerra, DC | 1 |
| Furtado, WR | 1 |
| Barbosa Coelho, E | 1 |
| Khitan, ZJ | 1 |
| Pan, Q | 1 |
| Appel, L | 1 |
| Bellovich, K | 1 |
| Fischer, MJ | 1 |
| Ham, LL | 1 |
| Jaar, BG | 1 |
| Kallem, RR | 2 |
| Rosas, SE | 1 |
| Beaubien-Souligny, W | 1 |
| Bezzaoucha, S | 1 |
| Pichette, V | 1 |
| Lafrance, JP | 1 |
| Bell, R | 1 |
| Lamarche, C | 1 |
| Ouimet, D | 1 |
| Vallee, M | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 1 |
| Gansevoort, RT | 1 |
| Katalinić, L | 1 |
| Blaslov, K | 1 |
| Pasini, E | 1 |
| Kes, P | 1 |
| Bašić-Jukić, N | 1 |
| Seras, M | 1 |
| Martín de Francisco, ÁL | 1 |
| Piñera, C | 1 |
| Gundin, S | 1 |
| García-Unzueta, M | 1 |
| Kislikova, M | 1 |
| Albines, Z | 1 |
| Serrano, M | 1 |
| Arias, M | 1 |
| Peride, I | 1 |
| Checheriţă, IA | 1 |
| Smarandache, DR | 1 |
| Rădulescu, D | 1 |
| Sinescu, RD | 1 |
| Niculae, A | 1 |
| Pricop, C | 1 |
| Ikizler, HO | 1 |
| Zelnick, L | 2 |
| Ruzinski, J | 1 |
| Curtin, L | 1 |
| Utzschneider, KM | 1 |
| Himmelfarb, J | 1 |
| Marano, M | 1 |
| Borrelli, S | 1 |
| Zamboli, P | 1 |
| Gulleroglu, K | 1 |
| Baskin, E | 1 |
| Moray, G | 1 |
| Haberal, M | 1 |
| Kuo, CC | 1 |
| Yeh, HC | 1 |
| Chen, B | 1 |
| Tsai, CW | 1 |
| Lin, YS | 1 |
| Huang, CC | 1 |
| Åsberg, A | 1 |
| Odsæter, IH | 1 |
| Mikkelsen, G | 1 |
| Hov, GG | 1 |
| Kim, JE | 1 |
| Scherzer, R | 1 |
| Estrella, MM | 1 |
| Basile, C | 1 |
| Rossi, L | 1 |
| Lomonte, C | 1 |
| Roy, J | 1 |
| Tao, K | 1 |
| Anderson, AH | 1 |
| Bansal, N | 1 |
| Deo, R | 1 |
| Feldman, HI | 2 |
| Kusek, JW | 1 |
| Lora, C | 1 |
| Ojo, AO | 1 |
| Shrama, K | 1 |
| Buttar, RS | 1 |
| Coco, M | 1 |
| Pena-Polanco, JE | 1 |
| Yenigun, EC | 1 |
| Aypak, C | 1 |
| Turgut, D | 1 |
| Aydin, MZ | 1 |
| Dede, F | 1 |
| Bellasi, A | 1 |
| Di Micco, L | 1 |
| Marzocco, S | 1 |
| De Simone, E | 1 |
| Cozzolino, M | 1 |
| Di Lullo, L | 1 |
| Guastaferro, P | 1 |
| Di Iorio, B | 1 |
| Chang, AR | 1 |
| Lash, J | 1 |
| Hsu, CY | 1 |
| Appel, LJ | 1 |
| Anderson, CA | 1 |
| Kendrick, JB | 1 |
| Chonchol, MB | 1 |
| Siscovick, D | 1 |
| Sarnak, M | 1 |
| Dad, T | 1 |
| Garimella, PS | 1 |
| Strom, JA | 1 |
| Havlín, J | 1 |
| Matoušovic, K | 1 |
| Vaňková, S | 1 |
| Schück, O | 1 |
| Disthabanchong, S | 1 |
| Treeruttanawanich, A | 1 |
| Imran, M | 1 |
| Shah, Y | 1 |
| Nundlall, S | 1 |
| Roberts, NB | 1 |
| Howse, M | 1 |
| Susantitaphong, P | 1 |
| Sewaralthahab, K | 1 |
| Balk, EM | 1 |
| Jaber, BL | 1 |
| Wei, G | 1 |
| Cheung, AK | 1 |
| Beddhu, S | 1 |
| Shao, Y | 1 |
| Ma, S | 1 |
| Tian, X | 1 |
| Wang, T | 1 |
| Xu, J | 1 |
| Hampel, DJ | 1 |
| Stoll, J | 1 |
| Nibbe, L | 1 |
| Gollasch, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)[NCT00327860] | 1,100 participants (Actual) | Observational | 2003-10-31 | Active, not recruiting | |||
| A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis[NCT03390842] | Phase 3 | 196 participants (Actual) | Interventional | 2017-12-20 | Completed | ||
| Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease[NCT01452412] | Phase 2/Phase 3 | 149 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis[NCT03710291] | Phase 3 | 1,480 participants (Actual) | Interventional | 2018-11-20 | Terminated (stopped due to Administrative reasons) | ||
| Chinese Cohort Study of Chronic Kidney Disease[NCT03041987] | 5,000 participants (Anticipated) | Observational | 2012-01-01 | Active, not recruiting | |||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis[NCT03317444] | Phase 3 | 217 participants (Actual) | Interventional | 2017-09-26 | Completed | ||
| Prospective Cohort Study of Chronic Renal Insufficiency[NCT00304148] | 5,499 participants (Anticipated) | Observational | 2003-07-31 | Active, not recruiting | |||
| Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.[NCT04117204] | 101 participants (Actual) | Interventional | 2019-06-01 | Completed | |||
| A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults[NCT03832166] | 142 participants (Actual) | Interventional | 2019-01-24 | Completed | |||
| Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate[NCT02743650] | 7 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Difficulties identifying subjects who were qualified to participate in the study) | |||
| A Prospective, Controlled, Randomized, Multicentric Study: Correction of Metabolic Acidosis With Use of Bicarbonate in Chronic Renal Insufficiency (CKD3b-4)[NCT01640119] | Phase 3 | 728 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change from baseline in serum bicarbonate at the end of treatment (Week 52). (NCT03390842)
Timeframe: Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| TRC101 Treatment Arm | 4.70 |
| Placebo Treatment Arm | 2.71 |
Change from baseline in the duration of repeated chair stand test at the end of treatment (Week 52). The five-times repeated chair stand test was used as a measure of lower extremity muscle strength. In this test, the time it took for a subject to repeatedly stand from a chair five times was recorded. This test is among the group of measures (gait speed, chair stand, and balance tests) comprising the Short Physical Performance Battery (SPPB), which has been used as a predictive tool for possible disability and for monitoring physical functioning in older people. (NCT03390842)
Timeframe: Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
| Intervention | seconds (Mean) |
|---|---|
| TRC101 Treatment Arm | -4.28 |
| Placebo Treatment Arm | -1.42 |
Change from baseline in the total score of the Kidney Disease Quality of Life Physical Function Domain (KDQOL-PFD) at the end of treatment. The KDQOL is a validated, kidney disease-specific measure of health-related quality of life. For study TRCA-301E, and the parent study TRCA-301, the 10-question Item 3 of the KDQOL, also known as the SF-36 Physical Function subscale, was selected to measure physical functioning and is referenced herein as the KDQOL-PFD. The KDQOL-PFD was chosen as a patient-reported outcome measurement to evaluate the effects of TRC101 on daily activities that may be adversely affected by loss of muscle caused by metabolic acidosis. The minimum score for each of the 10 questions is 0 (physical activity highly limited) and the maximum is 100 (physical activity not limited). The total KDQOL-PFD score is calculated by adding the scores for all 10 questions, for a minimum and maximum possible total KDQOL-PFD score of 0 or 100, respectively. (NCT03390842)
Timeframe: Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
| Intervention | KDQOL-PFD total score (Mean) |
|---|---|
| TRC101 Treatment Arm | 11.42 |
| Placebo Treatment Arm | -0.71 |
The incidence of adverse events (AEs), serious adverse events (SAEs) and AEs leading to withdrawal. For incidence of AEs and SAEs, see Adverse Events Section. For incidence of AEs leading to withdrawal, see endpoint values below. (NCT03390842)
Timeframe: Week 12 Visit in the parent study, TRCA-301, to the Week 54 Visit in the extension study, TRCA-301E.
| Intervention | percentage of participants (Number) |
|---|---|
| TRC101 Treatment Arm | 0 |
| Placebo Treatment Arm | 1.2 |
Percent of subjects having a change from baseline in serum bicarbonate of at least 4 mEq/L or bicarbonate in the normal range (22 - 29 mEq/L) at the end of treatment (Week 52). (NCT03390842)
Timeframe: Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
| Intervention | percentage of participants (Number) |
|---|---|
| TRC101 Treatment Arm | 62.7 |
| Placebo Treatment Arm | 37.8 |
The investigators will evaluate changes in bone mineral density at the wrist. (NCT01452412)
Timeframe: 2 year
| Intervention | g/cm2 (Mean) |
|---|---|
| Sodium Bicarbonate | 0.75 |
| Placebo | 0.73 |
Estimated GFR (NCT01452412)
Timeframe: 2 year
| Intervention | ml/min/1.73m2 (Mean) |
|---|---|
| Sodium Bicarbonate | 38.5 |
| Placebo | 36.3 |
Hand-grip strength will be measured in all participants (NCT01452412)
Timeframe: 2 year
| Intervention | kg (Mean) |
|---|---|
| Sodium Bicarbonate | 27.3 |
| Placebo | 24.9 |
Short Form- 36 (SF-36) will be performed in all participants. We will evaluate effects on the Physical Function Domain. The Physical Function Domain is scored from 0 to 100 with higher scores meaning better physical functioning. (NCT01452412)
Timeframe: 2 year
| Intervention | score on a scale (Mean) |
|---|---|
| Sodium Bicarbonate | 40 |
| Placebo | 43 |
Sit to stand to sit x10 speed (time to perform sit to stand to sit 10 times) will be measured and compared between groups. (NCT01452412)
Timeframe: 2 year
| Intervention | seconds (Mean) |
|---|---|
| Sodium Bicarbonate | 23.8 |
| Placebo | 22.9 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
Mean change from baseline to end of treatment (Week 12 Visit) in serum bicarbonate (NCT03317444)
Timeframe: Baseline to Week 12
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| TRC101 Treatment Arm | 4.42 |
| Placebo Treatment Arm | 1.78 |
Composite endpoint of the percentage of subjects having a change from baseline in serum bicarbonate ≥ 4 mEq/L or having serum bicarbonate in the normal range (22 - 29 mEq/L) at the end of treatment (Week 12 Visit). (NCT03317444)
Timeframe: Baseline to Week 12
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Subjects with change from baseline serum bicarbonate ≥ 4 mEq/L or serum bicarbonate in normal range | Subjects with change from baseline serum bicarbonate ≥ 4 mEq/L | Subjects with serum bicarbonate in normal range | |
| Placebo Treatment Arm | 22.5 | 21.3 | 16.9 |
| TRC101 Treatment Arm | 59.2 | 55.8 | 50.0 |
21 reviews available for hydrogen carbonate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease.
Topics: Acidosis; Bicarbonates; Cognitive Dysfunction; Humans; Motor Disorders; Renal Insufficiency, Chronic | 2021 |
Importance of Metabolic Acidosis as a Health Risk in Chronic Kidney Disease.
Topics: Acidosis; Alkalies; Bicarbonates; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Regulation of Acid-Base Balance in Patients With Chronic Kidney Disease.
Topics: Acid-Base Equilibrium; Acid-Base Imbalance; Animals; Bicarbonates; Citrates; Humans; Renal Insuffici | 2022 |
The Importance of Recognizing and Addressing the Spectrum of Acid Stress.
Topics: Bicarbonates; Humans; Kidney; Renal Insufficiency, Chronic | 2022 |
Sodium zirconium cyclosilicate and metabolic acidosis: Potential mechanisms and clinical consequences.
Topics: Acidosis; Bicarbonates; Humans; Hyperkalemia; Potassium; Renal Insufficiency, Chronic | 2023 |
Diet and Chronic Kidney Disease.
Topics: Acidosis; Animals; Bicarbonates; Diet, Vegetarian; Diet, Western; Dietary Proteins; Feeding Behavior | 2019 |
Chronic Metabolic Acidosis in Chronic Kidney Disease.
Topics: Acidosis; Animals; Bicarbonates; Bone Density; Chronic Disease; Diet Therapy; Disease Management; Hu | 2020 |
Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease.
Topics: Acidosis; Bicarbonates; Disease Progression; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Regulation of Acid-Base Balance in Chronic Kidney Disease.
Topics: Acid-Base Imbalance; Ammonia; Bicarbonates; Diet; Humans; Hydrogen-Ion Concentration; Renal Insuffic | 2017 |
Epidemiology of Acid-Base Derangements in CKD.
Topics: Acid-Base Equilibrium; Acid-Base Imbalance; Bicarbonates; Disease Progression; Humans; Prevalence; R | 2017 |
Management of the Metabolic Acidosis of Chronic Kidney Disease.
Topics: Acid-Base Equilibrium; Acidosis; Acidosis, Renal Tubular; Animals; Bicarbonates; Diet; Dietary Prote | 2017 |
Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2017 |
[Metabolic complications of chronic kidney disease].
Topics: Acidosis; Aged; Aged, 80 and over; Bicarbonates; Bradycardia; Calcium; Calcium, Dietary; Comorbidity | 2017 |
Hyperchloremic normal gap metabolic acidosis.
Topics: Acid-Base Equilibrium; Acidosis; Acidosis, Renal Tubular; Aldosterone; Ammonia; Bicarbonates; Buffer | 2019 |
Current status of bicarbonate in CKD.
Topics: Acidosis; Alkalies; Animals; Bicarbonates; Cardiovascular Diseases; Dietary Supplements; Humans; Ren | 2015 |
Metabolic Acidosis of CKD: An Update.
Topics: Acid-Base Equilibrium; Acidosis; Animals; Bicarbonates; Disease Progression; Glomerular Filtration R | 2016 |
The choice of dialysate bicarbonate: do different concentrations make a difference?
Topics: Acid-Base Equilibrium; Acidosis; Bicarbonates; Hemodialysis Solutions; Humans; Hydrogen-Ion Concentr | 2016 |
CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
Topics: Bicarbonates; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, | 2016 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
Consequences and therapy of the metabolic acidosis of chronic kidney disease.
Topics: Acidosis; Animals; Bicarbonates; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic | 2011 |
Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review.
Topics: Acidosis; Bicarbonates; Buffers; Creatinine; Glomerular Filtration Rate; Humans; Renal Insufficiency | 2012 |
20 trials available for hydrogen carbonate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
Topics: Acidosis; Aged; Bicarbonates; Double-Blind Method; Female; Humans; Middle Aged; Polymers; Renal Insu | 2022 |
Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study.
Topics: Acidosis; Bicarbonates; Humans; Potassium; Prospective Studies; Renal Insufficiency, Chronic | 2022 |
The New Nordic Renal Diet Induces a Pronounced Reduction of Urine Acid Excretion and Uremic Toxins in Chronic Kidney Disease Patients (Stage 3 and 4).
Topics: Acidosis; Ammonium Compounds; Bicarbonates; Diet; Humans; Renal Insufficiency, Chronic; Uremic Toxin | 2023 |
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
Topics: Acidosis; Bicarbonates; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate | 2023 |
Sodium Bicarbonate Treatment and Vascular Function in CKD: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Bicarbonates; Cardiovascular Diseases; Double-Blind Method; Humans; Prospective Studies; Pulse Wave | 2023 |
Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial.
Topics: Bicarbonates; Biomarkers; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up S | 2020 |
Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients.
Topics: Acidosis; Aged; Bicarbonates; Female; Humans; Kidney; Male; Middle Aged; Muscle, Skeletal; Renal Ins | 2020 |
Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial.
Topics: Acidosis; Aged; Bicarbonates; Biomarkers; Cost-Benefit Analysis; Double-Blind Method; Female; Humans | 2020 |
Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
Topics: Acidosis; Bicarbonates; Diabetes Mellitus; Humans; Polymers; Quality of Life; Renal Insufficiency, C | 2022 |
Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
Topics: Acid-Base Equilibrium; Acidosis; Aged; Bicarbonates; Biomarkers; Calcium Citrate; Cardiovascular Dis | 2019 |
Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
Topics: Acidosis; Adult; Aged; Aged, 80 and over; Bicarbonates; Cross-Linking Reagents; Double-Blind Method; | 2019 |
Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Topics: Acidosis; Administration, Oral; Aged; Bicarbonates; Double-Blind Method; Female; Humans; Male; Middl | 2019 |
Combined walking exercise and alkali therapy in patients with CKD4-5 regulates intramuscular free amino acid pools and ubiquitin E3 ligase expression.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Bicarbonates; Combined Modality Therapy; Exercise Thera | 2013 |
A low serum bicarbonate concentration as a risk factor for mortality in peritoneal dialysis patients.
Topics: Adult; Aged; Bicarbonates; C-Reactive Protein; Female; Follow-Up Studies; Humans; Male; Middle Aged; | 2013 |
Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Angiotensinogen; Bicarbonates; Biomarkers; Di | 2014 |
Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Angiotensinogen; Bicarbonates; Biomarkers; Di | 2014 |
Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Angiotensinogen; Bicarbonates; Biomarkers; Di | 2014 |
Treatment of metabolic acidosis in patients with stage 3 chronic kidney disease with fruits and vegetables or oral bicarbonate reduces urine angiotensinogen and preserves glomerular filtration rate.
Topics: Acid-Base Equilibrium; Acidosis; Administration, Oral; Angiotensinogen; Bicarbonates; Biomarkers; Di | 2014 |
The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients.
Topics: Acidosis; Adult; Aged; Allopurinol; Bicarbonates; Creatinine; Endothelium; Female; Gout Suppressants | 2015 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Haemodialysis session: the perfect storm for vascular calcification.
Topics: Acid-Base Imbalance; Aged; Aged, 80 and over; Bicarbonates; Calcium; Chronic Kidney Disease-Mineral | 2015 |
Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.
Topics: Acidosis; Aged; Bicarbonates; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycemic Age | 2016 |
Oral sodium bicarbonate improves thyroid function in predialysis chronic kidney disease.
Topics: Acidosis; Adult; Aged; Aged, 80 and over; Bicarbonates; Female; Humans; Male; Middle Aged; Prospecti | 2010 |
78 other studies available for hydrogen carbonate and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Low variability of plant protein intake in the CKiD cohort does not demonstrate changes in estimated GFR nor electrolyte balance.
Topics: Bicarbonates; Child; Glomerular Filtration Rate; Humans; Phosphorus; Plant Proteins; Plant Proteins, | 2022 |
Dyspepsia in Montenegrin chronic kidney disease patients undergoing hemodialysis: endoscopic and histopathological features.
Topics: Bicarbonates; Chronic Disease; Dyspepsia; Helicobacter Infections; Humans; Renal Dialysis; Renal Ins | 2022 |
Nutritional Status, Nutritional Phenotypes, and Oral Nutritional Supplement Prescription Patterns Among Patients With Non-Dialysis Chronic Kidney Disease in British Columbia.
Topics: Bicarbonates; British Columbia; Dietary Supplements; Humans; Malnutrition; Nutritional Status; Pheno | 2022 |
Lower bicarbonate level is associated with CKD progression and all-cause mortality: a propensity score matching analysis.
Topics: Acidosis; Adult; Aged; Aged, 80 and over; Bicarbonates; Cause of Death; Creatinine; Disease Progress | 2022 |
Effects of Oral Bicarbonate Supplementation on the Cardiovascular Risk Factors and Serum Nutritional Markers in Non-Dialysed Chronic Kidney Disease Patients.
Topics: Acidosis; Bicarbonates; Biomarkers; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; | 2022 |
Kidney-Metabolic Factors Associated with Cognitive Impairment in Chronic Kidney Disease: A Pilot Study.
Topics: Aged; Albuminuria; Bicarbonates; Carbon Dioxide; Cognitive Dysfunction; Cross-Sectional Studies; Glo | 2022 |
Is bicarbonate therapy effective in preventing CKD progression?
Topics: Bicarbonates; Disease Progression; Female; Humans; Kidney Failure, Chronic; Male; Renal Insufficienc | 2022 |
Serum bicarbonate levels and gait abnormalities in older adults: a cross-sectional study.
Topics: Aged; Bicarbonates; Cross-Sectional Studies; Gait; Gait Analysis; Humans; Renal Insufficiency, Chron | 2022 |
Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD.
Topics: Acidosis; Alkalies; Bicarbonates; Child; Disease Progression; Humans; Prospective Studies; Renal Ins | 2022 |
Demographic and clinical profile of black patients with chronic kidney disease attending a tertiary hospital in Johannesburg, South Africa.
Topics: Acidosis; Aged; Allopurinol; Anemia; Bicarbonates; Cross-Sectional Studies; Diabetes Mellitus; Doxaz | 2022 |
Trabecular bone score and phalangeal quantitative ultrasound are associated with muscle strength and fracture risk in hemodialysis patients.
Topics: Bicarbonates; Bone Density; Cancellous Bone; Fractures, Bone; Hand Strength; Humans; Lumbar Vertebra | 2022 |
Metabolic acidosis is undertreated and underdiagnosed: a retrospective cohort study.
Topics: Acidosis; Bicarbonates; Humans; Renal Insufficiency, Chronic; Retrospective Studies; Sodium Bicarbon | 2023 |
Relationship between Metabolic Acidosis and Chronic Kidney Disease Progression across Racial and Ethnic Groups: An Observational, Retrospective Cohort Study.
Topics: Acidosis; Bicarbonates; Cohort Studies; Ethnicity; Humans; Renal Insufficiency, Chronic; Retrospecti | 2022 |
Associations of Metabolic Syndrome and Abdominal Obesity with Anion Gap Metabolic Acidosis among US Adults.
Topics: Acid-Base Equilibrium; Acidosis; Adult; Bicarbonates; Humans; Metabolic Syndrome; Nutrition Surveys; | 2022 |
Associations of Metabolic Syndrome and Abdominal Obesity with Anion Gap Metabolic Acidosis among US Adults.
Topics: Acid-Base Equilibrium; Acidosis; Adult; Bicarbonates; Humans; Metabolic Syndrome; Nutrition Surveys; | 2022 |
Associations of Metabolic Syndrome and Abdominal Obesity with Anion Gap Metabolic Acidosis among US Adults.
Topics: Acid-Base Equilibrium; Acidosis; Adult; Bicarbonates; Humans; Metabolic Syndrome; Nutrition Surveys; | 2022 |
Associations of Metabolic Syndrome and Abdominal Obesity with Anion Gap Metabolic Acidosis among US Adults.
Topics: Acid-Base Equilibrium; Acidosis; Adult; Bicarbonates; Humans; Metabolic Syndrome; Nutrition Surveys; | 2022 |
No Good Deed: Acidosis in Chronic Kidney and Liver Disease.
Topics: Acidosis; Bicarbonates; Chronic Disease; Humans; Kidney; Liver Diseases; Liver Failure; Renal Insuff | 2023 |
Comprehensive Associations between Acidosis and the Skeleton in Patients with Kidney Disease.
Topics: Acidosis; Bicarbonates; Bone Density; Chronic Kidney Disease-Mineral and Bone Disorder; Cross-Sectio | 2023 |
Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: Results from the KNOW-CKD Study.
Topics: Acidosis; Adult; Aged; Ankle Brachial Index; Bicarbonates; Cholesterol; Cross-Sectional Studies; Fem | 2019 |
Serum Bicarbonate Concentration and Cause-Specific Mortality: The National Health and Nutrition Examination Survey 1999-2010.
Topics: Aged; Bicarbonates; Cardiovascular Diseases; Cause of Death; Cohort Studies; Correlation of Data; Fe | 2020 |
Low Serum Bicarbonate and CKD Progression in Children.
Topics: Acidosis; Adolescent; Bicarbonates; Buffers; Child; Child, Preschool; Disease Progression; Female; F | 2020 |
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
Topics: Bicarbonates; Blood Urea Nitrogen; Gastrointestinal Tract; Humans; Hyperkalemia; Male; Middle Aged; | 2021 |
Metabolic Acidosis and CKD Progression.
Topics: Acidosis; Ammonium Compounds; Animals; Bicarbonates; Citric Acid; Disease Progression; Humans; Hydro | 2021 |
Association of dietary acid load with serum bicarbonate in chronic kidney disease (CKD) patients.
Topics: Acids; Adult; Bicarbonates; Cross-Sectional Studies; Diet; Humans; Kidney; Renal Insufficiency, Chro | 2020 |
Serum lactate level may predict the development of acute kidney injury in acute decompensated heart failure.
Topics: Acute Kidney Injury; Aged; Bicarbonates; Biomarkers; Confidence Intervals; Creatinine; Female; Glome | 2020 |
Assessing Acid-Base Status in Patients With CKD: Does Measurement of Blood pH Matter?
Topics: Acid-Base Imbalance; Bicarbonates; Humans; Hydrogen-Ion Concentration; Prognosis; Renal Insufficienc | 2021 |
In older adults with CKD and mild acidosis, oral sodium bicarbonate did not improve physical function.
Topics: Acidosis; Aged; Bicarbonates; Humans; Renal Insufficiency, Chronic; Sodium Bicarbonate | 2020 |
Association of Pre-ESRD Serum Bicarbonate with Post-ESRD Mortality in Patients with Incident ESRD.
Topics: Aged; Bicarbonates; Disease Progression; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; | 2021 |
Metabolic acidosis is associated with increased risk of adverse kidney outcomes and mortality in patients with non-dialysis dependent chronic kidney disease: an observational cohort study.
Topics: Acidosis; Aged; Bicarbonates; Disease Progression; Female; Glomerular Filtration Rate; Humans; Incid | 2021 |
Acid Load and Phosphorus Homeostasis in CKD.
Topics: Acid-Base Equilibrium; Bicarbonates; Calcium; Cross-Sectional Studies; Female; Fibroblast Growth Fac | 2017 |
Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease.
Topics: Acidosis; Adolescent; Bicarbonates; Child; Disease Progression; Female; Follow-Up Studies; Glomerula | 2017 |
Clinical features and CKD-related quality of life in patients with CKD G3a and CKD G3b in China: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).
Topics: Adult; Anemia; Bicarbonates; Blood Pressure; China; Cholesterol, HDL; Cost of Illness; Female; Glome | 2017 |
New Frontiers in Treating Uremic Metabolic Acidosis.
Topics: Acidosis; Bicarbonates; Humans; Renal Insufficiency, Chronic; Uremia | 2018 |
Alkaline Diet and Metabolic Acidosis: Practical Approaches to the Nutritional Management of Chronic Kidney Disease.
Topics: Acid-Base Equilibrium; Acidosis; Animals; Bicarbonates; Bone and Bones; Diet; Dietary Proteins; Frui | 2018 |
Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers: Friend or foe?
Topics: Acidosis; Aged; Ankle Brachial Index; Bicarbonates; Biomarkers; Cardiovascular Diseases; Carotid Int | 2017 |
The Role of Bicarbonate in Cognition: Acidosis May Be Corrosive to the Brain.
Topics: Acidosis; Adult; Bicarbonates; Brain; Cognition; Humans; Renal Insufficiency, Chronic | 2018 |
A long term feed supplementation based on phosphate binders in Feline Chronic Kidney Disease.
Topics: Animal Feed; Animals; Bicarbonates; Cat Diseases; Cats; Dietary Supplements; Phosphorus; Renal Insuf | 2018 |
Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity-a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Bicarbonates; Calcinosis; Citric Acid; Female; Humans; Male; Middle | 2018 |
Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology.
Topics: Acidosis; Bicarbonates; Disease Progression; Humans; Nephrology; Poland; Renal Insufficiency, Chroni | 2018 |
It Is Really Time for Ammonium Measurement.
Topics: Acid-Base Equilibrium; Acidosis, Renal Tubular; Ammonium Compounds; Bicarbonates; Humans; Osmolar Co | 2018 |
Association between serum Na-Cl level and renal function decline in chronic kidney disease: results from the chronic kidney disease Japan cohort (CKD-JAC) study.
Topics: Acidosis; Aged; Anemia; Bicarbonates; Biomarkers; Disease Progression; Down-Regulation; Female; Glom | 2019 |
Metabolic acidosis in kidney transplant recipients.
Topics: Acidosis; Adult; Bicarbonates; Case-Control Studies; Female; Humans; Kidney Transplantation; Male; M | 2018 |
Elevated serum anion gap in adults with moderate chronic kidney disease increases risk for progression to end-stage renal disease.
Topics: Acid-Base Equilibrium; Adult; Aged; Bicarbonates; Biomarkers; Cross-Sectional Studies; Disease Progr | 2019 |
Retrospective study of the efficacy of oral potassium supplementation in cats with kidney disease.
Topics: Animal Feed; Animals; Bicarbonates; Cat Diseases; Cats; Diet; Dietary Supplements; Female; Hypokalem | 2020 |
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Adult; Aged; Bicarbonates; Cardiovascular Diseases; Cohort Studies; Disease Progression; Female; Hum | 2013 |
Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.
Topics: Bicarbonates; Blood Urea Nitrogen; Calcium; Chlorides; Creatinine; Endpoint Determination; Humans; H | 2013 |
Association of serum bicarbonate with clinical outcomes in CKD: could an increase in serum bicarbonate be a double-edged sword?
Topics: Bicarbonates; Cardiovascular Diseases; Female; Humans; Male; Renal Insufficiency, Chronic | 2013 |
Dietary acid intake and kidney disease progression in the elderly.
Topics: Acids; Aged; Bicarbonates; Diet, Protein-Restricted; Dietary Proteins; Disease Progression; Disease- | 2014 |
Association between serum bicarbonate levels and albuminuria in stage 3 and stage 4 chronic kidney disease: a cross-sectional study.
Topics: Aged; Albuminuria; Bicarbonates; Biomarkers; Chi-Square Distribution; Creatinine; Cross-Sectional St | 2014 |
Serum bicarbonate concentrations and kidney disease progression in community-living elders: the Health, Aging, and Body Composition (Health ABC) Study.
Topics: Acid-Base Imbalance; Aged; Albumins; Bicarbonates; Creatinine; Disease Progression; Female; Follow-U | 2014 |
Low serum bicarbonate and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA).
Topics: Acidosis; Aged; Albuminuria; Atherosclerosis; Bicarbonates; Cohort Studies; Creatinine; Cystatin C; | 2014 |
Prevalence of and risk factors for reduced serum bicarbonate in chronic kidney disease.
Topics: Acidosis; Adult; Aged; Bicarbonates; Biomarkers; Cross-Sectional Studies; Disease Progression; Down- | 2014 |
In chronic kidney disease, serum α-Klotho is related to serum bicarbonate and proteinuria.
Topics: Adult; Aging; Bicarbonates; Biomarkers; C-Reactive Protein; Creatinine; Cross-Sectional Studies; Fem | 2014 |
Metabolic Acidosis as a Possible Cause of CKD: What Should Clinicians Do?
Topics: Acidosis; Bicarbonates; Female; Humans; Male; Renal Insufficiency, Chronic | 2014 |
Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD stage 5D patients (MBD-5D).
Topics: Acidosis; Aged; Asian People; Bicarbonates; Bone Diseases; Female; Fractures, Bone; Humans; Male; Mi | 2014 |
Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case-controlled study.
Topics: Acidosis; Aged; Aged, 80 and over; Anemia; Bicarbonates; Calcium; Case-Control Studies; Creatine; Di | 2014 |
Impaired expression of key molecules of ammoniagenesis underlies renal acidosis in a rat model of chronic kidney disease.
Topics: Acidosis; Amino Acid Transport Systems, Neutral; Ammonia; Animals; Bicarbonates; Creatinine; Disease | 2015 |
Late referral for chronic kidney disease patients: nutritional point of view.
Topics: Acidosis; Aged; Anthropometry; Bicarbonates; Body Composition; Cross-Sectional Studies; Electric Imp | 2014 |
Elevated serum bicarbonate concentration in chronic kidney disease: a call to find the cause.
Topics: Bicarbonates; Female; Heart Failure; Humans; Male; Renal Insufficiency, Chronic | 2015 |
Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Bicarbonates; Disease Progression; Diuretics; Female; Glomerular Filtration Rate; Heart Failure; Hum | 2015 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Huma | 2015 |
[Acid-base status in patients treated with peritoneal dialysis].
Topics: Acid-Base Equilibrium; Acidosis; Adult; Aged; Bicarbonates; Buffers; Female; Hemodialysis Solutions; | 2014 |
Vascular calcification in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Aged; Albumins; Bicarbonates; C-Reactive Protein; Calcium; Female; Humans; Hypoparathyroidism | 2015 |
Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease.
Topics: Acidosis; Aged; Bicarbonates; Blood Glucose; Body Mass Index; Cross-Sectional Studies; Diet; Female; | 2016 |
pCO2 Reveals Arteriovenous Fistula Recirculation in Bicarbonate Hemodialysis (RecirCO2lation Test).
Topics: Aged; Aged, 80 and over; Area Under Curve; Arteriovenous Fistula; Bicarbonates; Biomarkers; Carbon D | 2016 |
Low-Grade Persistent Hyperparathyroidism After Pediatric Renal Transplant.
Topics: Adolescent; Age Factors; Bicarbonates; Biomarkers; Child; Female; Humans; Hyperparathyroidism; Kidne | 2016 |
Prevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study.
Topics: Acidosis; Adult; Aged; Bicarbonates; Chlorides; Cross-Sectional Studies; Diabetes Mellitus; Diet; Fe | 2015 |
Using the hazard ratio to evaluate allowable total error in predictive measurands.
Topics: Albumins; Bicarbonates; Calcium; Cholesterol; Humans; Phosphates; Proportional Hazards Models; Regre | 2016 |
Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans.
Topics: Adult; Anti-HIV Agents; Bicarbonates; HIV Infections; Humans; Male; Middle Aged; Renal Insufficiency | 2016 |
Serum Bicarbonate and Structural and Functional Cardiac Abnormalities in Chronic Kidney Disease - A Report from the Chronic Renal Insufficiency Cohort Study.
Topics: Aged; Bicarbonates; Cohort Studies; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; | 2016 |
Effect of metabolic acidosis on QT intervals in patients with chronic kidney disease.
Topics: Acidosis; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Bicarbonates; Electrocardiography; F | 2016 |
Higher net acid excretion is associated with a lower risk of kidney disease progression in patients with diabetes.
Topics: Acidosis; Acids; Aged; Ammonium Compounds; Bicarbonates; Biomarkers; Blood Urea Nitrogen; Diabetes M | 2017 |
Serum Bicarbonate Is Associated with Heart Failure in the Multi-Ethnic Study of Atherosclerosis.
Topics: Aged; Antihypertensive Agents; Atherosclerosis; Bicarbonates; Blood Pressure; Creatinine; Diuretics; | 2017 |
Quiz: An Unusual Case of Metabolic Alkalosis in a Patient With CKD.
Topics: Aged, 80 and over; Alkalosis; Antacids; Bicarbonates; Chelating Agents; Creatinine; Diagnosis, Diffe | 2017 |
[Metabolic acidosis in chronic kidney disease].
Topics: Acidosis; Bicarbonates; Disease Progression; Humans; Renal Dialysis; Renal Insufficiency, Chronic; S | 2016 |
Is blood ammonia influenced by kidney function? A prospective study.
Topics: Adult; Aged; Aged, 80 and over; Ammonia; Bicarbonates; Creatinine; Glomerular Filtration Rate; Human | 2012 |
High serum bicarbonate level within the normal range prevents the progression of chronic kidney disease in elderly chronic kidney disease patients.
Topics: Aged; Bicarbonates; Biomarkers; Female; Humans; Japan; Male; Prevalence; Renal Insufficiency, Chroni | 2013 |
Serum bicarbonate and mortality in adults in NHANES III.
Topics: Adult; Aged; Albuminuria; Bicarbonates; Biomarkers; Body Mass Index; Cardiovascular Diseases; Female | 2013 |
Dialysis adequacy in Chinese anuric peritoneal dialysis patients.
Topics: Adult; Aged; Anuria; Bicarbonates; Blood Pressure; China; Dialysis Solutions; Diet, Protein-Restrict | 2013 |
Hyperammonaemic encephalopathy and severe metabolic acidosis in a patient with chronic renal insufficiency years after ureterosigmoidostomy.
Topics: Acidosis; Aged; Bicarbonates; Blood Gas Analysis; Brain Diseases, Metabolic; Chlorides; Colostomy; E | 2007 |